Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
April 9, 2024
Assignee:
Translate Bio, Inc.
Inventors:
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Abstract: The present invention relates to methods for producing oxygenated terpenoids. Polynucleotides, derivative enzymes, and host cells for use in such methods are also provided.
Type:
Grant
Filed:
January 5, 2021
Date of Patent:
April 9, 2024
Assignee:
Manus Bio Inc.
Inventors:
Ajikumar Parayil Kumaran, Chin Giaw Lim, Liwei Li, Souvik Ghosh, Christopher Pirie, Anthony Qualley
Abstract: The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.
Type:
Grant
Filed:
November 12, 2020
Date of Patent:
April 9, 2024
Assignee:
Nuvation Bio Inc.
Inventors:
Son Minh Pham, Jayakanth Kankanala, Jeremy Pettigrew, Christopher Paul Miller
Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
April 9, 2024
Assignee:
Translate Bio, Inc.
Inventors:
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Abstract: This disclosure concerns an engineered polynucleotide that interacts with a pre-mRNA and a spliceosome to regulate gene expression. The engineered polynucleotide may have stem-loop structure that recruits the spliceosome and targeting sequences that are complementary to a target sequence at an exon-intron splice junction and may include nucleotides with 2? modifications and phorphorothioate linkages.
Abstract: Provided are high-filtration reusable face masks with replaceable filters. Reusable face masks can comprise a single piece mask body configured to cover a nose and a mouth of a human face and comprising at least one filter attachment port, wherein the at least one filter attachment port comprises a filter support structure, defines an opening in the mask body, and extends from the exterior surface of the mask body; wherein the at least one filter attachment port is configured to connect to a replaceable filter and support the replaceable filter by separating portions of filter media of the replaceable filter when the replaceable filter is attached to the at least one filter attachment port.
Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
Type:
Grant
Filed:
September 15, 2021
Date of Patent:
April 2, 2024
Assignee:
NURA BIO, INC.
Inventors:
Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
Type:
Grant
Filed:
June 15, 2022
Date of Patent:
April 2, 2024
Assignees:
Instil Bio (UK) Limited, Instil Bio, Inc.
Inventors:
John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
Type:
Grant
Filed:
July 13, 2022
Date of Patent:
April 2, 2024
Assignee:
Annapurna Bio, Inc.
Inventors:
Haifeng Tang, Michael Hanson, Sarah Boyce, Zhe Nie
Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.
Type:
Grant
Filed:
March 9, 2023
Date of Patent:
March 26, 2024
Assignee:
Solarea Bio, Inc.
Inventors:
Eric Michael Schott, Maria Juliana Soto-Giron, Gerardo V. Toledo
Abstract: The present disclosure relates to a benzoselenophene-based compound, a method of preparing the benzoselenophene-based compound, and a pharmaceutical composition and antibody-drug conjugate including the benzoselenophene-based compound.
Type:
Grant
Filed:
July 29, 2022
Date of Patent:
March 26, 2024
Assignee:
AIMED BIO INC.
Inventors:
Dongyeol Lim, Min Cheol Kim, Amol Mhetre, Do-Hyun Nam
Abstract: Systems, devices, and methods for localizing magnets are useful for biological tissue analysis and other applications. Tissue analysis systems for use with a tissue analysis device may include a storage medium storing computer readable instructions that cause the execution of magnet localization methods. The system may include the tissue analysis device, which includes a magnet and a magnetometer array disposed adjacent to the magnet. When executed by a processor, the instructions cause operations, including recording a magnetic field of the magnet with the magnetometer array, simulating a simulated magnetic field at each magnetometer of the magnetometer array, and estimating positional information of the magnet based upon iterating simulated positional information of the simulated magnet.
Abstract: The present invention enables simultaneous and stable expression of a plurality of foreign genes by using a stealthy RNA gene expression system that is a complex that does not activate the innate immune mechanism and is formed from an RNA-dependent RNA polymerase, a single-strand RNA binding protein, and negative-sense single-strand RNAs including the following (1) to (8): (1) a target RNA sequence that codes for any protein or functional RNA; (2) an RNA sequence forming a noncoding region and derived from mRNA expressed in animal cells; (3) a transcription initiation signal sequence recognized by the RNA-dependent RNA polymerase; (4) a transcription termination signal sequence recognized by the polymerase; (5) an RNA sequence containing a replication origin recognized by the polymerase; (6) an RNA sequence that codes for the polymerase and of which codons are optimized for the species from which an introduction target cell is derived; (7) an RNA sequence that codes for a protein for regulating the activity o
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
March 12, 2024
Assignees:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TOKIWA-BIO INC.
Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.
Type:
Grant
Filed:
May 19, 2021
Date of Patent:
March 5, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Michael Heartlein, Frank DeRosa, Anusha Dias
Abstract: Provided herein are systems and methods for screening desirable biological variants using a high-throughput integrated system. The integrated system may be configured to input a plurality of parameters from functional studies of biological variants under applied conditions, in conjunction with integrated libraries of biological variants, and filter the inputs to produce desirable biological variants based on an input performance requirement. The system may output optimized strains, molecules, or novel molecules expected to have a desirable functional characteristic. Accordingly, the methods and systems disclosed herein enable multi-parametric studies of biological diversity and conditional diversity in systems biology.
Type:
Grant
Filed:
December 20, 2022
Date of Patent:
March 5, 2024
Assignee:
TRIPLEBAR BIO, INC.
Inventors:
Jeremy Agresti, Andres Ornelas Vargas, Kevin Gregory Hoff
Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
February 27, 2024
Assignee:
IVERIC bio, Inc.
Inventors:
Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.